GlassScriptPhysician profile
Abel Fernando Gutierrez
NPI 1932942745
$2,755.51
in general payments reported to CMS, 2019-2025
33 companies · $1,868 in 2025
The $1,868 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $887 · 2025: $1,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,755.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $439.32 | 2024-2025 | Impella |
| Abbvie INC. | $299.71 | 2024-2025 | |
| Novo Nordisk INC | $274.90 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Xeris Pharmaceuticals, INC. | $269.43 | 2024-2025 | Recorlev |
| Pfizer INC. | $193.28 | 2024-2025 | |
| Lilly USA, LLC | $168.02 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $165.12 | 2024-2025 | Verquvo |
| Axsome Therapeutics, INC. | $92.26 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $87.23 | 2024-2025 | Rexulti |
| Shield Therapeutics INC | $61.66 | 2024-2025 | |
| Lundbeck LLC | $59.06 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $58.31 | 2024-2025 | Farxiga |
| Viatris Specialty LLC | $56.09 | 2025 | Yupelri |
| Verity Pharmaceuticals INC. | $52.46 | 2025 | Tlando |
| Amgen INC. | $48.32 | 2024-2025 | Evenity, Prolia, Otezla |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $41.59 | 2025 | Fanapt |
| Exact Sciences Corporation | $39.31 | 2024-2025 | Cologuard Collection Kit |
| Nalu Medical, INC. | $32.02 | 2025 | Nalu Neurostimulation System |
| Mylan Specialty L.P. | $30.84 | 2024 | Yupelri |
| Recordati_rare_diseases_inc. | $30.61 | 2025 | Isturisa |
| Mayne Pharma Commercial LLC | $29.61 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.05 | 2024 | |
| Hologic Sales and Service, LLC | $24.69 | 2024 | Thinprep 2000 Processor |
| Antares Pharma, INC. | $22.18 | 2024 | Xyosted |
| Phathom Pharmaceuticals, INC. | $20.66 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $19.56 | 2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.40 | 2024 | Jardiance |
| Corcept Therapeutics | $18.43 | 2025 | Korlym |
| Neurocrine Biosciences, INC. | $17.00 | 2024 | |
| Dexcom, INC. | $15.40 | 2025 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $15.30 | 2025 | Nuzyra |
| Organon LLC | $13.86 | 2024 | |
| Ironwood Pharmaceuticals, INC | $13.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abel Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.